Ritu Baral
Stock Analyst at TD Cowen
(2.82)
# 1,887
Out of 5,058 analysts
38
Total ratings
48.39%
Success rate
7.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ritu Baral
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Maintains: Buy | $65 → $97 | $98.80 | -1.82% | 2 | Nov 6, 2025 | |
| RNA Avidity Biosciences | Downgrades: Hold | $78 → $74 | $71.01 | +4.21% | 2 | Oct 29, 2025 | |
| INSM Insmed | Maintains: Buy | $154 → $193 | $206.94 | -6.74% | 4 | Oct 2, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $35 → $39 | $23.50 | +65.99% | 2 | Sep 11, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $390 → $554 | $568.15 | -2.49% | 2 | Aug 26, 2025 | |
| AKRO Akero Therapeutics | Initiates: Buy | $76 | $54.36 | +39.81% | 1 | Aug 4, 2025 | |
| SPRO Spero Therapeutics | Downgrades: Hold | n/a | $2.37 | - | 4 | Nov 18, 2024 | |
| ANTX AN2 Therapeutics | Downgrades: Hold | n/a | $1.08 | - | 2 | Nov 18, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $282 → $371 | $457.20 | -18.85% | 4 | Oct 21, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | n/a | $8.07 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $175 | $17.48 | +901.14% | 1 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $110.14 | - | 2 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.62 | - | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $14.49 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.03 | - | 2 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $29.15 | - | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $27.60 | - | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.55 | - | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.48 | - | 2 | Jul 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $546.25 | - | 2 | Jan 12, 2018 |
Palvella Therapeutics
Nov 6, 2025
Maintains: Buy
Price Target: $65 → $97
Current: $98.80
Upside: -1.82%
Avidity Biosciences
Oct 29, 2025
Downgrades: Hold
Price Target: $78 → $74
Current: $71.01
Upside: +4.21%
Insmed
Oct 2, 2025
Maintains: Buy
Price Target: $154 → $193
Current: $206.94
Upside: -6.74%
ACADIA Pharmaceuticals
Sep 11, 2025
Maintains: Buy
Price Target: $35 → $39
Current: $23.50
Upside: +65.99%
Madrigal Pharmaceuticals
Aug 26, 2025
Maintains: Buy
Price Target: $390 → $554
Current: $568.15
Upside: -2.49%
Akero Therapeutics
Aug 4, 2025
Initiates: Buy
Price Target: $76
Current: $54.36
Upside: +39.81%
Spero Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.37
Upside: -
AN2 Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.08
Upside: -
Alnylam Pharmaceuticals
Oct 21, 2024
Maintains: Buy
Price Target: $282 → $371
Current: $457.20
Upside: -18.85%
Sagimet Biosciences
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $8.07
Upside: -
Mar 22, 2023
Maintains: Outperform
Price Target: $125 → $175
Current: $17.48
Upside: +901.14%
Nov 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $110.14
Upside: -
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.62
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $14.49
Upside: -
Jul 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.03
Upside: -
Jun 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $29.15
Upside: -
Mar 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $27.60
Upside: -
Jun 29, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.55
Upside: -
Jul 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $3.48
Upside: -
Jan 12, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $546.25
Upside: -